In the Phase 2b CARE study, the investigational drug, cenerimod, demonstrated safe and effective results for treatment of ...

Objective Juvenile SLE (jSLE) is an autoimmune disease characterised by the presence of high levels of autoantibodies, ...

Controlling cardiovascular risk factors and maintaining long-term disease remission mitigated the increased risk for ...

We described the first case reported in the literature of multiple myeloma in a young African woman with Systemic lupus and Sjögren Syndrome. The clinician should consider multiple myeloma in young ...

Patients with SLE have a higher prevalence of primary headaches vs those with RA or pSS, but similar percentages were found ...

Belantamab mafodotin is under clinical development by GSK and currently in Phase I for Systemic Lupus Erythematosus.

ALM-223 is under clinical development by Almirall and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 73% phase ...

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with systemic lupus erythematosus (SLE) ...

The presence of antiarrestin autoantibodies among patients with SLE is associated with an increased risk of developing HCQ-related retinal toxicity.

Columnist Candace Semien praises the community's ability to survive and thrive without guilt while living with lupus.